Tumor microenvironment diversity and plasticity in cancer multidrug resistance.

[1]  Yao Fu,et al.  Nanotechnology-based ocular drug delivery systems: recent advances and future prospects , 2023, Journal of Nanobiotechnology.

[2]  G. Hannon,et al.  FOXC2 promotes vasculogenic mimicry and resistance to anti-angiogenic therapy. , 2023, Cell reports.

[3]  Shondra M. Pruett-Miller,et al.  Stromal-induced epithelial-mesenchymal transition induces targetable drug resistance in acute lymphoblastic leukemia , 2023, Cell reports.

[4]  N. Hoch.  Tissue specificity of DNA damage and repair. , 2023, Physiology.

[5]  R. J. Anto,et al.  Curcuminoids as Anticancer Drugs: Pleiotropic Effects, Potential for Metabolic Reprogramming and Prospects for the Future , 2023, Pharmaceutics.

[6]  Subhasmita Mahapatra,et al.  The FGF/FGFR signalling mediated anti-cancer drug resistance and therapeutic intervention , 2023, Journal of biomolecular structure & dynamics.

[7]  C. Bashor,et al.  Tumor-associated macrophages induce inflammation and drug resistance in a mechanically tunable engineered model of osteosarcoma. , 2023, Biomaterials.

[8]  R. Kaiser,et al.  Anti-angiogenic agents for NSCLC following first-line immunotherapy: Rationale, recent updates, and future perspectives. , 2023, Lung cancer.

[9]  Anubhab Mukherjee,et al.  Lung cancer immunotherapy: progress, pitfalls, and promises , 2023, Molecular Cancer.

[10]  J. Minna,et al.  CD70 is a therapeutic target upregulated in EMT-associated EGFR tyrosine kinase inhibitor resistance. , 2023, Cancer cell.

[11]  Junhao Wu,et al.  Therapeutic strategies of dual-target small molecules to overcome drug resistance in cancer therapy. , 2023, Biochimica et biophysica acta. Reviews on cancer.

[12]  H. Saya,et al.  IDH2 stabilizes HIF‐1α‐induced metabolic reprogramming and promotes chemoresistance in urothelial cancer , 2023, The EMBO journal.

[13]  Zhigang Wang,et al.  Nanoenabled Tumor Energy Metabolism Disorder via Sonodynamic Therapy for Multidrug Resistance Reversal and Metastasis Inhibition. , 2022, ACS applied materials & interfaces.

[14]  Greg M. Delgoffe,et al.  Hypoxia drives CD39-dependent suppressor function in exhausted T cells to limit antitumor immunity , 2022, Nature Immunology.

[15]  Qiang Zhou,et al.  Reprogramming transcription after DNA damage: recognition, response, repair, and restart. , 2022, Trends in cell biology.

[16]  P. Gao,et al.  Immune checkpoint inhibitor resistance in hepatocellular carcinoma. , 2022, Cancer letters.

[17]  Rudranil De,et al.  Immunometabolic attributes and mitochondria-associated signaling of Tumor-Associated Macrophages in tumor microenvironment modulate cancer progression. , 2022, Biochemical pharmacology.

[18]  Wang Xiao-yan,et al.  Metabolic reprogramming of glutamine involved in tumorigenesis, multidrug resistance and tumor immunity. , 2022, European journal of pharmacology.

[19]  Xuyang Zhu,et al.  Liquid exfoliation of ultrasmall zirconium carbide nanodots as a noninflammatory photothermal agent in the treatment of glioma. , 2022, Biomaterials.

[20]  Kirthanashri S. Vasanthan,et al.  Precision medicine: Ray of hope in overcoming cancer multidrug resistance. , 2022, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[21]  N. Tumino,et al.  Myeloid derived suppressor cells in tumor microenvironment: Interaction with innate lymphoid cells. , 2022, Seminars in immunology.

[22]  Shiaw-Yih Lin,et al.  Tumor microenvironment: barrier or opportunity towards effective cancer therapy , 2022, Journal of Biomedical Science.

[23]  J. Wolchok,et al.  Clinical implications of T cell exhaustion for cancer immunotherapy , 2022, Nature Reviews Clinical Oncology.

[24]  E. Lee,et al.  Prevalence and mechanisms of somatic deletions in single human neurons during normal aging and in DNA repair disorders , 2022, Nature Communications.

[25]  Zhe-Sheng Chen,et al.  Progress in the studies on the molecular mechanisms associated with multidrug resistance in cancers , 2022, Acta pharmaceutica Sinica. B.

[26]  Zhonghui Tang,et al.  The primordial differentiation of tumor-specific memory CD8+ T cells as bona fide responders to PD-1/PD-L1 blockade in draining lymph nodes , 2022, Cell.

[27]  Jennifer S. Yu,et al.  H3.3-G34 mutations impair DNA repair and promote cGAS/STING-mediated immune responses in pediatric high-grade glioma models , 2022, The Journal of clinical investigation.

[28]  Wen-Hao Li,et al.  Rational Design of T-Cell- and B-Cell-Based Therapeutic Cancer Vaccines. , 2022, Accounts of chemical research.

[29]  Xingliang Dai,et al.  Cancer Cell Membrane-Coated C-TiO2 Hollow Nanoshells for Combined Sonodynamic and Hypoxia-Activated Chemotherapy. , 2022, Acta biomaterialia.

[30]  Kwok-Kin Wong,et al.  The current state of the art and future trends in RAS-targeted cancer therapies , 2022, Nature Reviews Clinical Oncology.

[31]  T. Lammers,et al.  Cancer-associated Fibroblasts: Origin, Function, Imaging, and Therapeutic Targeting. , 2022, Advanced drug delivery reviews.

[32]  V. Boussiotis,et al.  The complex role of tumor-infiltrating macrophages , 2022, Nature Immunology.

[33]  S. Gerber,et al.  Toll-like receptor 7/8 agonist R848 alters the immune tumor microenvironment and enhances SBRT-induced antitumor efficacy in murine models of pancreatic cancer , 2022, Journal for ImmunoTherapy of Cancer.

[34]  Jing Gao,et al.  Shaping Polarization Of Tumor-Associated Macrophages In Cancer Immunotherapy , 2022, Frontiers in Immunology.

[35]  Chunbo Li,et al.  Dissecting the Single-Cell Transcriptome Network of Immune Environment Underlying Cervical Premalignant Lesion, Cervical Cancer and Metastatic Lymph Nodes , 2022, Frontiers in Immunology.

[36]  D. Qujeq,et al.  CRISPR/Cas9 gene editing: a new approach for overcoming drug resistance in cancer , 2022, Cellular & Molecular Biology Letters.

[37]  Hao Cai,et al.  Immunogenic Cell Death Activates the Tumor Immune Microenvironment to Boost the Immunotherapy Efficiency , 2022, Advanced science.

[38]  Crispin J. Miller,et al.  Cancer-associated fibroblasts require proline synthesis by PYCR1 for the deposition of pro-tumorigenic extracellular matrix , 2022, Nature Metabolism.

[39]  Yin Lu,et al.  Pharmacological manipulation of Ezh2 with Salvianolic acid B results in tumor vascular normalization and synergizes with cisplatin and T cell-mediated immunotherapy. , 2022, Pharmacological research.

[40]  Qing Ji,et al.  Tumor-Associated Macrophages Regulate PD-1/PD-L1 Immunosuppression , 2022, Frontiers in Immunology.

[41]  S. Ray,et al.  Targeting tumor hypoxia and hypoxia-inducible factors (HIFs) for the treatment of cancer- A story of transcription factors with novel approach in molecular medicine. , 2022, Current molecular medicine.

[42]  Chaohua Hu,et al.  CDK6-PI3K signaling axis is an efficient target for attenuating ABCB1/P-gp mediated multi-drug resistance (MDR) in cancer cells , 2022, Molecular cancer.

[43]  Runhui Liu,et al.  Heterochiral β-Peptide Polymers Combating Multidrug-Resistant Cancers Effectively without Inducing Drug Resistance. , 2022, Journal of the American Chemical Society.

[44]  X. Dai,et al.  Copper-based nanomaterials for cancer theranostics. , 2022, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology.

[45]  C. Pan,et al.  CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy , 2022, Journal of experimental & clinical cancer research : CR.

[46]  A. Ke,et al.  Current applications and future perspective of CRISPR/Cas9 gene editing in cancer , 2022, Molecular Cancer.

[47]  F. Ginhoux,et al.  Hypoxia‐driven immunosuppression by Treg and type‐2 conventional dendritic cells in HCC , 2022, Hepatology.

[48]  N. Kumari,et al.  Tumor-associated macrophages in cancer: recent advancements in cancer nanoimmunotherapies , 2022, Journal of experimental & clinical cancer research : CR.

[49]  J. Duan,et al.  AHSA1 is a promising therapeutic target for cellular proliferation and proteasome inhibitor resistance in multiple myeloma , 2022, Journal of Experimental & Clinical Cancer Research.

[50]  S. Peters,et al.  Managing Resistance to Immune Checkpoint Inhibitors in Lung Cancer: Treatment and Novel Strategies. , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  Hyun-Ju Park,et al.  A novel C-terminal heat shock protein 90 inhibitor that overcomes STAT3-Wnt-β-catenin signaling-mediated drug resistance and adverse effects , 2022, Theranostics.

[52]  B. Bulutoglu,et al.  Engineering interferons and interleukins for cancer immunotherapy. , 2022, Advanced drug delivery reviews.

[53]  Zhenfeng Wu,et al.  Hypoxia responsive nano-drug delivery system based on angelica polysaccharide for liver cancer therapy , 2021, Drug delivery.

[54]  Xueda Hu,et al.  Pan-cancer single-cell landscape of tumor-infiltrating T cells , 2021, Science.

[55]  Xiguang Chen,et al.  Tumor-Associated Macrophages: Critical Players in Drug Resistance of Breast Cancer , 2021, Frontiers in Immunology.

[56]  X. Zhai,et al.  Novel imidazo[1,2-a]pyridine derivatives as potent ATX allosteric inhibitors: Design, synthesis and promising in vivo anti-fibrotic efficacy in mice lung model. , 2021, Bioorganic chemistry.

[57]  J. Fletcher,et al.  Targeting multidrug resistance-associated protein 1 (MRP1)-expressing cancers: Beyond pharmacological inhibition. , 2021, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[58]  Chunhong Li,et al.  Nanoparticle-based delivery systems modulate the tumor microenvironment in pancreatic cancer for enhanced therapy , 2021, Journal of Nanobiotechnology.

[59]  G. Semenza,et al.  HIF-1–regulated expression of calreticulin promotes breast tumorigenesis and progression through Wnt/β-catenin pathway activation , 2021, Proceedings of the National Academy of Sciences.

[60]  Qingming Ma,et al.  Normalization of the tumor microvasculature based on targeting and modulation of the tumor microenvironment. , 2021, Nanoscale.

[61]  J. Zhang,et al.  Traditional Chinese medicine reverses cancer multidrug resistance and its mechanism , 2021, Clinical and Translational Oncology.

[62]  N. Chaput,et al.  Tumour burden and efficacy of immune-checkpoint inhibitors , 2021, Nature Reviews Clinical Oncology.

[63]  D. Gabrilovich,et al.  Myeloid-Derived Suppressor Cells: A Propitious Road to Clinic. , 2021, Cancer discovery.

[64]  Chen Liang,et al.  Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives , 2021, Molecular Cancer.

[65]  M. Greene,et al.  Regulatory T Cells: Regulation of Identity and Function , 2021, Frontiers in Immunology.

[66]  Zihai Li,et al.  Combination strategies to maximize the benefits of cancer immunotherapy , 2021, Journal of Hematology & Oncology.

[67]  M. Baek,et al.  M1 macrophage exosomes engineered to foster M1 polarization and target the IL-4 receptor inhibit tumor growth by reprogramming tumor-associated macrophages into M1-like macrophages. , 2021, Biomaterials.

[68]  P. Yin,et al.  Bufalin suppresses tumour microenvironment-mediated angiogenesis by inhibiting the STAT3 signalling pathway , 2021, Journal of Translational Medicine.

[69]  O. Mir,et al.  Modulating tumor-associated macrophages to enhance the efficacy of immune checkpoint inhibitors: A TAM-pting approach. , 2021, Pharmacology & therapeutics.

[70]  G. Semenza.  Breakthrough Science: Hypoxia-Inducible Factors, Oxygen Sensing, and Disorders of Hematopoiesis. , 2021, Blood.

[71]  Arunandan Kumar,et al.  Elucidating the mechanisms of Temozolomide resistance in gliomas and the strategies to overcome the resistance. , 2021, Biochimica et biophysica acta. Reviews on cancer.

[72]  Y. Assaraf,et al.  Novel nanomedicines to overcome cancer multidrug resistance. , 2021, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[73]  Zhuang Liu,et al.  Liquid exfoliation of TiN nanodots as novel sonosensitizers for photothermal-enhanced sonodynamic therapy against cancer , 2021 .

[74]  D. Brat,et al.  Hypoxia-inducible factors individually facilitate inflammatory myeloid metabolism and inefficient cardiac repair , 2021, The Journal of experimental medicine.

[75]  David R. Jones,et al.  Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers , 2021, Nature.

[76]  R. Bernards,et al.  EGFR activation limits the response of liver cancer to lenvatinib , 2021, Nature.

[77]  Shuqiang Li,et al.  Phenotype, specificity and avidity of antitumour CD8+ T cells in melanoma , 2021, Nature.

[78]  E. Wherry,et al.  Epigenetic scarring of exhausted T cells hinders memory differentiation upon eliminating chronic antigenic stimulation , 2021, Nature Immunology.

[79]  D. Vignali,et al.  Regulatory T Cells: Barriers of Immune Infiltration Into the Tumor Microenvironment , 2021, Frontiers in Immunology.

[80]  I. Shapiro,et al.  The role of HIF proteins in maintaining the metabolic health of the intervertebral disc , 2021, Nature Reviews Rheumatology.

[81]  Yulei N. Wang,et al.  Cancer‐associated fibroblasts: Key players in shaping the tumor immune microenvironment , 2021, Immunological reviews.

[82]  Ruixin Wu,et al.  Bufalin targets the SRC-3/MIF pathway in chemoresistant cells to regulate M2 macrophage polarization in colorectal cancer. , 2021, Cancer letters.

[83]  M. Merad,et al.  MDSC: Markers, development, states, and unaddressed complexity. , 2021, Immunity.

[84]  P. Bolla,et al.  Drug Resistance in Metastatic Breast Cancer: Tumor Targeted Nanomedicine to the Rescue , 2021, International journal of molecular sciences.

[85]  Margaret M. Billingsley,et al.  Delivery technologies for T cell gene editing: Applications in cancer immunotherapy , 2021, EBioMedicine.

[86]  Haojun Yang,et al.  27-Hydroxycholesterol is a specific factor in the neoplastic microenvironment of HCC that causes MDR via GRP75 regulation of the redox balance and metabolic reprogramming , 2021, Cell Biology and Toxicology.

[87]  Xiaofeng Liu,et al.  Sec62 promotes stemness and chemoresistance of human colorectal cancer through activating Wnt/β-catenin pathway , 2021, Journal of experimental & clinical cancer research : CR.

[88]  N. Matsumura,et al.  Tumor Immune Microenvironment during Epithelial–Mesenchymal Transition , 2021, Clinical Cancer Research.

[89]  M. Bruchez,et al.  Monotherapy and Combination Therapy Using Anti‐Angiogenic Nanoagents to Fight Cancer , 2021, Advanced materials.

[90]  D. Zheng,et al.  Molecular Features of Cancer-associated Fibroblast Subtypes and their Implication on Cancer Pathogenesis, Prognosis, and Immunotherapy Resistance , 2021, Clinical Cancer Research.

[91]  Na Liu,et al.  Chemotherapeutic and targeted agents can modulate the tumor microenvironment and increase the efficacy of immune checkpoint blockades , 2021, Molecular cancer.

[92]  Yongfeng Ding,et al.  Exhausted CD8+T Cells in the Tumor Immune Microenvironment: New Pathways to Therapy , 2021, Frontiers in Immunology.

[93]  S. Catrina,et al.  Hypoxia and hypoxia-inducible factors in diabetes and its complications , 2021, Diabetologia.

[94]  Saurabh Singh,et al.  CRISPR/Cas mediated epigenome editing for cancer therapy. , 2021, Seminars in cancer biology.

[95]  M. Rescigno,et al.  Mitochondrial metabolic reprogramming controls the induction of immunogenic cell death and efficacy of chemotherapy in bladder cancer , 2021, Science Translational Medicine.

[96]  J. Larkin,et al.  Enhancing anti-tumour efficacy with immunotherapy combinations , 2020, The Lancet.

[97]  Ting Zhang,et al.  Tumor-Associated Macrophages in Tumor Immunity , 2020, Frontiers in Immunology.

[98]  Dihua Yu,et al.  Tumor microenvironment as a therapeutic target in cancer. , 2020, Pharmacology & therapeutics.

[99]  Ashley M. Jacobi,et al.  CRISPR-Cas9 genome editing using targeted lipid nanoparticles for cancer therapy , 2020, Science Advances.

[100]  Chun-Yuan Chen,et al.  Lactate-induced MRP1 expression contributes to metabolism-based etoposide resistance in non-small cell lung cancer cells , 2020, Cell communication and signaling : CCS.

[101]  Y. Jing,et al.  Baseline immunity and impact of chemotherapy on immune microenvironment in cervical cancer , 2020, British Journal of Cancer.

[102]  J. Rothstein,et al.  Metabolic support of tumor-infiltrating regulatory T cells by lactic acid , 2020, Nature.

[103]  F. Tang,et al.  Single-Cell Multiomics Sequencing Reveals Prevalent Genomic Alterations in Tumor Stromal Cells of Human Colorectal Cancer. , 2020, Cancer cell.

[104]  Zhipeng Gu,et al.  Nanotechnology-based drug delivery systems for enhanced diagnosis and therapy of oral cancer. , 2020, Journal of materials chemistry. B.

[105]  P. Cheng,et al.  Targeting tumor-associated macrophages for cancer immunotherapy. , 2020, Biochimica et biophysica acta. Reviews on cancer.

[106]  A. Harris,et al.  HIFs, angiogenesis, and metabolism: elusive enemies in breast cancer. , 2020, The Journal of clinical investigation.

[107]  W. Lee,et al.  Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity , 2020, Experimental & Molecular Medicine.

[108]  L. Zitvogel,et al.  Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors , 2020, Nature Reviews Clinical Oncology.

[109]  A. Ianaro,et al.  The New Era of Cancer Immunotherapy: Targeting Myeloid-Derived Suppressor Cells to Overcome Immune Evasion , 2020, Frontiers in Immunology.

[110]  Shuhua Wei,et al.  Regulatory T cells in tumor microenvironment: new mechanisms, potential therapeutic strategies and future prospects , 2020, Molecular Cancer.

[111]  I. Melero,et al.  Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies. , 2020, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[112]  K. Pietras,et al.  Heterogeneity of cancer‐associated fibroblasts: Opportunities for precision medicine , 2020, Cancer science.

[113]  D. Tuveson,et al.  DIVERSITY AND BIOLOGY OF CANCER-ASSOCIATED FIBROBLASTS. , 2020, Physiological reviews.

[114]  Xiaojing Zhang,et al.  Apatinib as targeted therapy for advanced bone and soft tissue sarcoma: a dilemma of reversing multidrug resistance while suffering drug resistance itself , 2020, Angiogenesis.

[115]  L. Roshangar,et al.  Tumor microenvironment complexity and therapeutic implications at a glance , 2020, Cell Communication and Signaling.

[116]  J. Pollard,et al.  Tumor-associated macrophages , 2020, Current Biology.

[117]  Ke Xu,et al.  Bufalin reverses multidrug resistance by regulating stemness through the CD133/nuclear factor‐κB/MDR1 pathway in colorectal cancer , 2020, Cancer science.

[118]  Deepak Kgk,et al.  Tumor Microenvironment: Challenges and Opportunities in Targeting Metastasis of Triple Negative Breast Cancer. , 2020, Pharmacological research.

[119]  T. Schumacher,et al.  CD8+ T cell states in human cancer: insights from single-cell analysis , 2020, Nature Reviews Cancer.

[120]  S. Sakaguchi,et al.  Regulatory T Cells and Human Disease. , 2020, Annual review of immunology.

[121]  T. Muranen,et al.  The Interplay of the Extracellular Matrix and Stromal Cells as a Drug Target in Stroma-Rich Cancers. , 2020, Trends in pharmacological sciences.

[122]  S. Teichmann,et al.  A cell atlas of human thymic development defines T cell repertoire formation , 2020, Science.

[123]  Thea D. Tlsty,et al.  A framework for advancing our understanding of cancer-associated fibroblasts , 2020, Nature Reviews Cancer.

[124]  Qiu-Shen Chen,et al.  SFI Enhances Therapeutic Efficiency of Gefitinib: An Insight into Reversal of Resistance to Targeted Therapy in Non-small Cell Lung Cancer Cells , 2020, Journal of Cancer.

[125]  Y. Assaraf,et al.  Advanced technological tools to study multidrug resistance in cancer. , 2020, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[126]  A. Weeraratna,et al.  How the ageing microenvironment influences tumour progression , 2019, Nature Reviews Cancer.

[127]  A. C. Gasparovic,et al.  Phospholipids and cholesterol: Inducers of cancer multidrug resistance and therapeutic targets. , 2019, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[128]  T. Mohr,et al.  Computational approaches in cancer multidrug resistance research: Identification of potential biomarkers, drug targets and drug-target interactions. , 2019, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[129]  Yuanyuan Liu,et al.  pH and redox dual-responsive nanoparticles based on disulfide-containing poly(β-amino ester) for combining chemotherapy and COX-2 inhibitor to overcome drug resistance in breast cancer , 2019, Journal of Nanobiotechnology.

[130]  D. Adelson,et al.  An effective drug sensitizing agent increases gefitinib treatment by down regulating PI3K/Akt/mTOR pathway and up regulating autophagy in non-small cell lung cancer. , 2019, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[131]  Xin Liang,et al.  Hypoxia Induces Drug Resistance in Colorectal Cancer through the HIF-1α/miR-338-5p/IL-6 Feedback Loop. , 2019, Molecular therapy : the journal of the American Society of Gene Therapy.

[132]  T. Kietzmann,et al.  DUBs, Hypoxia, and Cancer. , 2019, Trends in cancer.

[133]  Ying Wang,et al.  Degradation of MCL-1 by bufalin reverses acquired resistance to osimertinib in EGFR-mutant lung cancer. , 2019, Toxicology and applied pharmacology.

[134]  Y. Assaraf,et al.  The multi-factorial nature of clinical multidrug resistance in cancer. , 2019, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[135]  H. Mirzaei,et al.  Targeting regulatory T cells by Curcumin: A potential for cancer immunotherapy. , 2019, Pharmacological research.

[136]  Jie Zheng,et al.  Toward Normalization of the Tumor Microenvironment for Cancer Therapy , 2019, Integrative cancer therapies.

[137]  R. Nibbs,et al.  Understanding and overcoming the resistance of cancer to PD-1/PD-L1 blockade. , 2019, Pharmacological research.

[138]  Guan Sun,et al.  Mechanisms and therapeutic potentials of cancer immunotherapy in combination with radiotherapy and/or chemotherapy. , 2019, Cancer letters.

[139]  M. V. von Herrath,et al.  Regulatory Immune Mechanisms beyond Regulatory T Cells. , 2019, Trends in immunology.

[140]  Hsin-Hung Chen,et al.  Indocyanine green/doxorubicin-encapsulated functionalized nanoparticles for effective combination therapy against human MDR breast cancer. , 2019, Colloids and surfaces. B, Biointerfaces.

[141]  N. Zhang,et al.  The Preparation, Determination of a Flexible Complex Liposome Co-Loaded with Cabazitaxel and β-Elemene, and Animal Pharmacodynamics on Paclitaxel-Resistant Lung Adenocarcinoma , 2019, Molecules.

[142]  Jiansong Ji,et al.  CRISPR-Cas9 for cancer therapy: Opportunities and challenges. , 2019, Cancer letters.

[143]  G. Stassi,et al.  Cancer-associated fibroblasts as abettors of tumor progression at the crossroads of EMT and therapy resistance , 2019, Molecular Cancer.

[144]  Siling Wang,et al.  Tumor Microenvironment‐Activatable Prodrug Vesicles for Nanoenabled Cancer Chemoimmunotherapy Combining Immunogenic Cell Death Induction and CD47 Blockade , 2019, Advanced materials.

[145]  Xu Zhou,et al.  Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy , 2019, Nature Medicine.

[146]  A. R. Fernandes,et al.  Targeting Tumor Microenvironment for Cancer Therapy , 2019, International journal of molecular sciences.

[147]  J. Galon,et al.  Approaches to treat immune hot, altered and cold tumours with combination immunotherapies , 2019, Nature Reviews Drug Discovery.

[148]  T. Kietzmann,et al.  Hypoxia-Inducible Factor Prolyl 4-Hydroxylases and Metabolism. , 2018, Trends in molecular medicine.

[149]  I. Melero,et al.  Cytokines in clinical cancer immunotherapy , 2018, British Journal of Cancer.

[150]  R. Weinberg,et al.  New insights into the mechanisms of epithelial–mesenchymal transition and implications for cancer , 2018, Nature Reviews Molecular Cell Biology.

[151]  Qiuyu Zhao,et al.  Shenqi Fuzheng Injection Reverses Cisplatin Resistance through Mitofusin-2-Mediated Cell Cycle Arrest and Apoptosis in A549/DDP Cells , 2018, Evidence-based complementary and alternative medicine : eCAM.

[152]  C. Liu,et al.  Increasing the anticancer performance of bufalin (BUF) by introducing an endosome-escaping polymer and tumor-targeting peptide in the design of a polymeric prodrug. , 2018, Colloids and surfaces. B, Biointerfaces.

[153]  M. Fehlings,et al.  Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates , 2018, Nature.

[154]  D. Waxman,et al.  Immunogenic chemotherapy: Dose and schedule dependence and combination with immunotherapy. , 2018, Cancer letters.

[155]  D. Gabrilovich,et al.  Plasticity of myeloid-derived suppressor cells in cancer. , 2018, Current opinion in immunology.

[156]  P. Carmeliet,et al.  Targeting angiogenic metabolism in disease , 2018, Science.

[157]  Dai Fukumura,et al.  Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges , 2018, Nature Reviews Clinical Oncology.

[158]  R. Kerbel,et al.  Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa , 2018, Nature Reviews Clinical Oncology.

[159]  V. Mittal.  Epithelial Mesenchymal Transition in Tumor Metastasis. , 2018, Annual review of pathology.

[160]  D. Gabrilovich,et al.  Myeloid-derived suppressor cells coming of age , 2018, Nature Immunology.

[161]  A. Lamprecht,et al.  MDR in cancer: Addressing the underlying cellular alterations with the use of nanocarriers. , 2017, Pharmacological research.

[162]  A. Harris,et al.  Advances in Hypoxia-Inducible Factor Biology. , 2017, Cell metabolism.

[163]  G. Ren,et al.  Curcumin Enhances the Anticancer Effect Of 5-fluorouracil against Gastric Cancer through Down-Regulation of COX-2 and NF- κB Signaling Pathways , 2017, Journal of Cancer.

[164]  K. Tatsumi,et al.  Pirfenidone may revert the epithelial-to-mesenchymal transition in human lung adenocarcinoma. , 2017, Oncology letters.

[165]  A. Griffioen,et al.  Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy? , 2017, Angiogenesis.

[166]  Qingling Zhang,et al.  Resveratrol reverses Doxorubicin resistance by inhibiting epithelial-mesenchymal transition (EMT) through modulating PTEN/Akt signaling pathway in gastric cancer , 2017, Journal of Experimental & Clinical Cancer Research.

[167]  Terje Johansen,et al.  Microenvironmental autophagy promotes tumour growth , 2017, Nature.

[168]  M. Esteller,et al.  IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models. , 2016, Gastroenterology.

[169]  N. Greig,et al.  Engineered Nanoparticles Against MDR in Cancer: The State of the Art and its Prospective. , 2016, Current pharmaceutical design.

[170]  Y. Assaraf,et al.  Overcoming ABC transporter-mediated multidrug resistance: Molecular mechanisms and novel therapeutic drug strategies. , 2016, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[171]  W. Jäger,et al.  NF-κB contributes to MMP1 expression in breast cancer spheroids causing paracrine PAR1 activation and disintegrations in the lymph endothelial barrier in vitro , 2015, Oncotarget.

[172]  M. Zou,et al.  Mitochondrial ROS and cancer drug resistance: Implications for therapy. , 2015, Pharmacological research.

[173]  Elaine Fuchs,et al.  TGF-β Promotes Heterogeneity and Drug Resistance in Squamous Cell Carcinoma , 2015, Cell.

[174]  Liyan Jiang,et al.  Curcumin lowers erlotinib resistance in non-small cell lung carcinoma cells with mutated EGF receptor. , 2014, Oncology research.

[175]  Zhe-Sheng Chen,et al.  β-Elemene, a compound derived from Rhizoma zedoariae, reverses multidrug resistance mediated by the ABCB1 transporter. , 2014, Oncology reports.

[176]  S. Mattarollo,et al.  Combining low-dose or metronomic chemotherapy with anticancer vaccines , 2013, Oncoimmunology.

[177]  Ling Xu,et al.  Bufalin Reverses HGF-Induced Resistance to EGFR-TKIs in EGFR Mutant Lung Cancer Cells via Blockage of Met/PI3k/Akt Pathway and Induction of Apoptosis , 2013, Evidence-based complementary and alternative medicine : eCAM.

[178]  K. Nan,et al.  Activation of PI3 kinase/Akt/HIF-1α pathway contributes to hypoxia-induced epithelial-mesenchymal transition and chemoresistance in hepatocellular carcinoma. , 2011, International journal of oncology.

[179]  R. Morita,et al.  Smad2 and Smad3 Are Redundantly Essential for the TGF-β–Mediated Regulation of Regulatory T Plasticity and Th1 Development , 2010, The Journal of Immunology.

[180]  F. Oswald,et al.  The Notch signaling pathway: Transcriptional regulation at Notch target genes , 2009, Cellular and Molecular Life Sciences.

[181]  S. Artavanis-Tsakonas,et al.  Myc is a Notch1 transcriptional target and a requisite for Notch1-induced mammary tumorigenesis in mice. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[182]  M. Gottesman,et al.  Targeting multidrug resistance in cancer , 2006, Nature Reviews Drug Discovery.

[183]  Manfred Gessler,et al.  The Notch target genes Hey1 and Hey2 are required for embryonic vascular development. , 2004, Genes & development.

[184]  W. May,et al.  Survival function of ERK1/2 as IL-3-activated, staurosporine-resistant Bcl2 kinases. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[185]  S Paget,et al.  THE DISTRIBUTION OF SECONDARY GROWTHS IN CANCER OF THE BREAST. , 1889 .

[186]  Robin Parihar,et al.  Myeloid-Derived Suppressor Cells in the Tumor Microenvironment. , 2020, Advances in experimental medicine and biology.

[187]  A. Farooqi,et al.  Targeting of JAK-STAT Signaling in Breast Cancer: Therapeutic Strategies to Overcome Drug Resistance. , 2019, Advances in experimental medicine and biology.

[188]  Y. Assaraf,et al.  Redundant angiogenic signaling and tumor drug resistance. , 2018, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[189]  A. Oro,et al.  GLI activation by atypical protein kinase C ι/λ regulates the growth of basal cell carcinomas. , 2016 .

[190]  Zhe-Sheng Chen,et al.  The modulation of ABC transporter-mediated multidrug resistance in cancer: a review of the past decade. , 2015, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[191]  L. Lanier,et al.  TGF-beta downregulates the activating receptor NKG2D on NK cells and CD8+ T cells in glioma patients. , 2010, Neuro-oncology.